Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

70.91
-1.1800-1.64%
Post-market: 70.910.00000.00%19:30 EDT
Volume:3.08M
Turnover:216.76M
Market Cap:9.86B
PE:-9.87
High:71.79
Open:71.54
Low:69.31
Close:72.09
52wk High:88.31
52wk Low:44.91
Shares:139.02M
Float Shares:138.02M
Volume Ratio:1.68
T/O Rate:2.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1827
EPS(LYR):-6.5400
ROE:-572.15%
ROA:-28.09%
PB:-56.82
PE(LYR):-10.84

Loading ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 16

Cytokinetics CEO Robert I. Blum Disposes of 7,500 Common Shares for $615,150

Reuters
·
Jul 15

How Myqorzo’s US and German Launches Will Impact Cytokinetics (CYTK) Investors

Simply Wall St.
·
Jul 12

Larimar, Cytokinetics, Itau, Global-e, Immunovant Shake-Up

TIPRANKS
·
Jul 11

High-Profile Insider Trade Shakes Up Cytokinetics Watchlist

TIPRANKS
·
Jul 08

Cytokinetics EVP R&D Malik Fady Ibraham Disposes of 3,500 Common Shares Worth $303,170

Reuters
·
Jul 08

Cytokinetics is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 08

RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating

MT Newswires Live
·
Jul 07

Cytokinetics Releases ESC 2026 Late-breaking Abstracts Update

Reuters
·
Jul 07

Cytokinetics Announces Three Late-breaking Science Abstracts at the European Society of Cardiology (esc) Congress 2026

THOMSON REUTERS
·
Jul 07

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

GlobeNewswire
·
Jul 07

CYTK, PRME, DOCS, WBD, LQDA Trending With Analysts

TIPRANKS
·
Jul 04

Top Cytokinetics Insiders Quietly Cash In With Major Stock Sales

TIPRANKS
·
Jul 03

Cytokinetics CFO Sung Lee Disposes of 1,112 Common Shares for $97,618.48

Reuters
·
Jul 03

Cytokinetics CFO Lee Sung Reports Sale of 3,134 Common Shares Valued at $266,390

Reuters
·
Jun 30

Cytokinetics Seen Gaining From Myqorzo Momentum to Treat Heart Conditions, UBS Says

MT Newswires Live
·
Jun 30

Cytokinetics Raised to Buy from Neutral by UBS

Dow Jones
·
Jun 30

Cytokinetics Inc : UBS Raises to Buy from Neutral

THOMSON REUTERS
·
Jun 29

UBS Upgrades Cytokinetics to Buy From Neutral, Adjusts Price Target to $115 From $69

MT Newswires Live
·
Jun 29

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Cytokinetics (CYTK)

TIPRANKS
·
Jun 29